What is the prevalence of Non-Hodgkin's lymphoma?

Non-Hodgkin's lymphoma is a group of blood cancers that is relatively common compared to ultra-rare diseases, with an estimated prevalence of over 500,000 individuals currently living with the diagnosis in the United States alone. While incidence rates vary by subtype, approximately 80,000 new cases of Non-Hodgkin's lymphoma are diagnosed annually in the U.S., making it one of the most frequently occurring types of lymphoma.

What is the incidence and prevalence of Non-Hodgkin's lymphoma?

According to the National Cancer Institute's SEER database, the lifetime risk of developing Non-Hodgkin's lymphoma is approximately 1 in 41. While it is not classified as a "rare" disease by standard definitions, the vast diversity of its subtypes—such as follicular lymphoma or diffuse large B-cell lymphoma—means that specific variants can be quite rare. It is important to note that global prevalence data for Non-Hodgkin's lymphoma can be challenging to aggregate due to inconsistencies in cancer registry reporting and potential underdiagnosis in regions with limited diagnostic infrastructure.

Who is most affected by Non-Hodgkin's lymphoma?

The risk of developing Non-Hodgkin's lymphoma increases significantly with age, with the median age at diagnosis being approximately 67 years. Regarding gender distribution, Non-Hodgkin's lymphoma is slightly more common in males than in females. While the disease can occur in children, it is significantly more prevalent in the adult population. Geographic and ethnic variations exist, with higher incidence rates often observed in developed nations, though this may reflect better screening and diagnostic capabilities rather than biological predisposition alone.

What factors complicate epidemiological data?

• Subtype complexity: Non-Hodgkin's lymphoma encompasses over 60 distinct subtypes, complicating uniform data collection.


• Diagnostic evolution: Improvements in pathology and molecular testing mean that cases once labeled "unclassified" are now accurately identified, shifting historical prevalence statistics.


• Community insights: At DiseaseMaps.org, 96 people with Non-Hodgkin's lymphoma have joined our community, providing vital, real-world data that complements clinical statistics by highlighting the patient experience beyond raw numbers.

Next steps

• Consult with a hematologist-oncologist to understand your specific subtype of Non-Hodgkin's lymphoma.


• Connect with the community at DiseaseMaps.org to share experiences with others living with Non-Hodgkin's lymphoma.


• Review current clinical trials via the NIH/NCI database if you are seeking information on emerging therapeutic options.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• National Cancer Institute (NCI) SEER Program: Cancer Stat Facts: Non-Hodgkin Lymphoma.


• American Cancer Society: Key Statistics for Non-Hodgkin Lymphoma.


• Orphanet: Rare diseases and their classifications regarding specific lymphoma subtypes.


• NIH National Cancer Institute: PDQ® Cancer Information Summaries.